提取物对绝经后骨质疏松症的治疗效果。
Treatment effect of extract on postmenopausal osteoporosis .
作者信息
Ouyang Lu, Zhang Qiufang, Ruan Xuzhi, Feng Yibin, Wang Xuanbin
机构信息
Laboratory of Chinese Herbal Pharmacology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China ; School of Pharmacy, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Laboratory of Chinese Herbal Pharmacology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China ; School of Pharmacy, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China ; Basic School of Medicine, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
出版信息
Exp Ther Med. 2014 Jun;7(6):1687-1690. doi: 10.3892/etm.2014.1661. Epub 2014 Apr 2.
extract (BSHY), a traditional Chinese medicine, has been demonstrated to treat postmenopausal osteoporosis, however, the underlying mechanism remains to be fully elucidated. The aim of the present study was to investigate the therapeutic effect of BSHY and the mechanisms underlying this effect in an postmenopausal osteoporosis animal model. A total of 1 g BSHY containing 7.12 μg icariin was prepared. Low-dose BSHY (BSHY-L; 11.1 g/kg), medium-dose BSHY (BSHY-M; 22.2 g/kg) and high-dose BSHY (BSHY-H; 44.4 g/kg) was administered to oophorectomized rats using intragastric infusion. Estradiol (E2), interleukin-6 (IL-6) and serum alkaline phosphatase (ALP) levels, as well as bone density, were determined. It was found that the levels of serum ALP in the BSHY-L, BSHY-M and BSHY-H groups (197.75±41.74, 166.63±44.83 and 165.63±44.90 IU/l, respectively) were significantly decreased compared with the model group (299.13±45.79 IU/l; P<0.05), whilst the levels of E2 (16.89±1.71, 17.95±1.40 and 18.34±1.43 pg/ml, respectively) increased compared with the model group (14.54±1.61; P<0.05). In addition, the levels of IL-6 decreased in the BSHY-L, BSHY-M and BSHY-H groups (91.85±14.81, 82.99±15.65 and 80.54±14.61 pg/ml, respectively) compared with the model group (105.93±16.50 pg/ml; P<0.05). Furthermore, it was demonstrated that BSHY increased the bone density in the BSHY-L, BSHY-M and BSHY-H groups (0.20±0.014, 0.22±0.016 and 0.22±0.017 g/cm, respectively) compared with the model group (0.19±0.011 g/cm; P<0.05). BSHY was also found to increase the number of osteoblasts in the BSHY-L, BSHY-M and BSHY-H groups (25.38±2.17, 29.25±2.12 and 30.00±2.39, respectively), compared with in the model group (14.75±2.38; P<0.05), and decrease the number of osteoclasts in the BSHY-L, BSHY-M and BSHY-H groups (4.00±1.85, 4.25±1.39 and 5.75±1.49, respectively) compared with 9.50±1.60 observed in the model group (P<0.05). These results suggest that BSHY is a potential therapeutic drug for the treatment of osteoporosis . Furthermore, these results suggest that the mechanism by which BSHY decreases the serum levels of IL-6 may be by regulating E2.
中药补骨还阳提取物（BSHY）已被证明可治疗绝经后骨质疏松症，然而，其潜在机制仍有待充分阐明。本研究的目的是在绝经后骨质疏松症动物模型中研究BSHY的治疗效果及其作用机制。制备了含7.12μg淫羊藿苷的1g BSHY。采用灌胃法将低剂量BSHY（BSHY-L；11.1g/kg）、中剂量BSHY（BSHY-M；22.2g/kg）和高剂量BSHY（BSHY-H；44.4g/kg）给予去卵巢大鼠。测定雌二醇（E2）、白细胞介素-6（IL-6）和血清碱性磷酸酶（ALP）水平以及骨密度。结果发现，BSHY-L、BSHY-M和BSHY-H组的血清ALP水平（分别为197.75±41.74、166.63±44.83和165.63±44.90IU/l）与模型组（299.13±45.79IU/l；P<0.05）相比显著降低，而E2水平（分别为16.89±1.71、17.95±1.40和18.34±1.43pg/ml）与模型组（14.54±1.61；P<0.05）相比升高。此外，BSHY-L、BSHY-M和BSHY-H组的IL-6水平（分别为91.85±14.81、82.99±15.65和80.54±14.61pg/ml）与模型组（105.93±16.50pg/ml；P<0.05）相比降低。此外，与模型组（0.19±0.011g/cm；P<0.05）相比，BSHY-L、BSHY-M和BSHY-H组的骨密度增加（分别为0.20±0.014、0.22±0.016和0.22±0.017g/cm）。还发现，与模型组（14.75±2.38；P<0.05）相比，BSHY-L、BSHY-M和BSHY-H组的成骨细胞数量增加（分别为25.38±2.17、29.25±2.12和30.00±2.39）；与模型组观察到的9.50±1.60相比，BSHY-L、BSHY-M和BSHY-H组的破骨细胞数量减少（分别为4.00±1.85、4.25±1.39和5.75±1.49；P<0.05）。这些结果表明，BSHY是一种治疗骨质疏松症的潜在治疗药物。此外，这些结果表明，BSHY降低血清IL-6水平的机制可能是通过调节E2。
Zotero 插件